Tag: Medical Research
Spotlight on Immunotherapy: Genetic Makeup of Tumors Informs use of anti-PD-1 drugs for Multiple Cancer Types
By Pooja H. Rambhia, MD Candidate, Case Western Reserve University | 6 October 2017 In News, Science, Treatment
Imagine the powerlessness one must feel after undergoing rigorous treatment for cancer only to find that your tumor is non-responsive. However – new hope may be on the horizon. In May 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Pembrolizumab for treatmentof patients whose cancers possess a genetic mutation in the mismatch repair pathway (mismatch repair deficient, or dMMR) or are microsatellite instability-high (MSI-H). This is the first time the agency approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.
Bristol-Myers Squibb Funds Two MRA Young Investigator Awards in Immuno-Oncology
By Kristen Mueller, Ph.D., MRA Scientific Program Director | 6 September 2017 In Allies & Partnerships, Science, Treatment
MRA is pleased to announce Bristol-Myers Squibb (BMS) has provided generous support for two Young Investigator Awards from our 2016-2017 grant cycle. The recipients of the Bristol-Myers Squibb - MRA Young Investigator Award are Dr. Erica Stone of The Wistar Institute and Dr. Manuel Valiente of Fundación Centro Nacional de Investigaciones Oncológicas Carlos III. MRA’s independent panel of academic experts selected these two immuno-oncology research programs to receive funding in 2017.
Melanoma Research Progress At Stake in Washington Brinksmanship
27 September 2013 In News
When you live and work in Washington, D.C., it’s easy to forget that most people don’t follow bills as they move through the legislative process or have Senate Sub-Committee homepages bookmarked in their browsers. Most people are moving forward with their daily lives, despite whatever Congressional posturing or scandal is...
NIH Director Dr. Francis Collins Explains Why Redheads are at Risk for Melanoma
4 September 2013 In News
A new blog entry by National Institutes of Health (NIH) Director Dr. Francis Collins offers a great explanation of recent research findings that are starting to unravel the mystery of why redheads are more susceptible to melanoma. According to Dr. Collins, the research was supported by NIH funding.